{"id":"W3021157979","doi":"10.1101/2020.05.11.20093146","title":"Nilotinib in Patients with Advanced Parkinson’s Disease: A Randomized Phase 2A Study (NILO-PD)","year":2020,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Michael J. Fox Foundation for Parkinson's Research","keywords":"Tolerability; Placebo; Medicine; Internal medicine; Parkinson's disease; Nilotinib; Montreal Cognitive Assessment; Adverse effect; Disease; Dementia; Tyrosine kinase","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005050646,0.0008148965,0.002540088,0.0002976253,0.00006184465,0.00003748832,0.0004096877,0.0001432454,0.0001879658],"category_scores_gemma":[0.000657468,0.000618252,0.0003106206,0.000412351,0.0002447689,0.0001228286,0.0003946302,0.001175027,0.00003335231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002986047,"about_ca_system_score_gemma":0.0004641741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003410239,"about_ca_topic_score_gemma":0.00002788784,"domain_scores_codex":[0.995461,0.0004805127,0.000984105,0.001443926,0.001057084,0.000573408],"domain_scores_gemma":[0.9970802,0.0002239045,0.0005882099,0.001250506,0.0002642743,0.0005928722],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5031883,0.004156552,0.4760893,0.0004236421,0.0006218079,0.0003731017,0.001700705,0.0002151169,0.00002914041,0.000009821523,0.00001521282,0.01317737],"study_design_scores_gemma":[0.5592971,0.001078418,0.4337262,0.0009734742,0.0007231168,0.000001508142,0.0002053636,0.0001634974,0.0000385673,0.0003779618,0.002808623,0.0006061624],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858254,0.001428481,0.0008574088,0.001285517,0.0005031839,0.009507447,0.0001453179,0.000290683,0.0001565526],"genre_scores_gemma":[0.9942803,0.00007776765,0.00186347,0.0005586399,0.000251737,0.002331421,0.0003124851,0.000186983,0.0001372314],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05610891,"threshold_uncertainty_score":0.9996269,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01805245375242769,"score_gpt":0.307098422350753,"score_spread":0.2890459685983253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}